Advanced breast cancer Trials in San Francisco, United States
Conditions / Advanced breast cancer / San Francisco, United States
Clinical trials for Advanced breast cancer investigate a range of treatment strategies and patient populations.
10 total trials for this combination
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06157892 | A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors | RECRUITING | PHASE2 |
| NCT02091960 | A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer | COMPLETED | PHASE2 |
| NCT06993844 | Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors | RECRUITING | PHASE1/PHASE2 |
| NCT06625775 | Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors | RECRUITING | PHASE1 |
| NCT02657889 | Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer | COMPLETED | PHASE1/PHASE2 |
| NCT02069093 | Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer | COMPLETED | PHASE2 |
| NCT06982521 | Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer | RECRUITING | PHASE3 |
| NCT04188548 | A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer | ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT06638307 | A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer | RECRUITING | PHASE1 |
| NCT05323955 | Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib | ACTIVE_NOT_RECRUITING | PHASE2 |